Novartis Ag

Surya Prakash Ayalasomayajula

Fabian Chen

Christopher Bush

Gesine Winzenburg

Masha Berkhin

Bernd Trueby

The present invention relates to a solid unit oral dosage form comprising sacubitril and valsartan in a 1:1 molar ratio, preferably in the form of the so-called angiotensin receptor neprilysin inhibitor (ARNI) LCZ696, which is a complex salt hydrate of sacubitril, valsartan, and sodium ions, appropriate for use in pediatrics or other patients where low and individual dosing is required or who encounter problems with swallowing e.g. as a result of a disease or because of age, to the manufacture of said solid dosage form and to invention embodiments relating to therapy using said dosage form.

Growing community of inventors

East Hanover, NJ, United States of America

Surya Prakash Ayalasomayajula